๐ฌDeep Research
GDRX โ GoodRx Holdings ยท catalysts, narrative & risks
GoodRx Holdings (GDRX) โ Research Brief as of 2026-10-27
Recent Catalysts (last ~1โ3 months)
Q2 2026 earnings (early August 2026). GoodRx reported Q2 2026 results in early August (Aug 5 per [4], Aug 6 per [8]). Top-line results beat consensus: revenue of $200.41M (down 1.3% YoY but above the ~$193.23M consensus estimate) and EPS of $0.08, meeting estimates [4]. Segment growth was strong โ Pharma Direct revenue up 76% YoY and subscriptions up 39% YoY โ prompting the company to raise full-year revenue and EBITDA guidance [8].
AI-assisted research from the K3vl4r desk โ not personalized investment advice. More research โ